This article is more than 5 years old. Information may no longer be current.
Alimera to host webinar for launch of Iluvien to treat DME
Click Here to Manage Email Alerts
Alimera Sciences will host a live webinar for eye care professionals to help launch Iluvien for the treatment of diabetic macular edema, according to a press release.
“We chose this novel webinar launch approach in order to disseminate information about Iluvien to [the retinal community] as efficiently and effectively as possible. It is our hope that by providing this open discussion platform, physicians will feel empowered to take advantage of this cutting-edge treatment option and make it quickly available to their appropriate DME patients,” Dan Myers, president and CEO of Alimera, said in the release.
The webinar will be held on Monday, March 2, at 8:30 p.m. EST. Initial shipments of Iluvien (fluocinolone acetonide intravitreal implant) will begin on Monday, Feb. 23.
The 1-hour webinar, consisting of eight retina specialists and one glaucoma specialist, will feature case studies, previously recorded injections and a live audience Q&A, the release said. Alimera executives will also be available to answer questions.
For more information and registration, go to www.iluvien.com.